Innovus Pharmaceuticals Inc (INNV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Products Id :- GDPH399494D
|
Pages: 92
|
March 2018
|
Region: North America
|

Request for Sample Report

Request A Quote

Executive Summary

Summary

Innovus Pharmaceuticals Inc (Innovus Pharmaceuticals), formerly North Horizon Inc is a pharmaceutical company that commercialize, license and develops over-the-counter and consumer healthcare products. The company's product portfolio comprises BTH testosterone booster; Zestra for female arousal; EjectDelay for premature ejaculation; FlutiCare OTC for Allergic Rhinitis; and Sensum for the indication of reduced penile sensitivity. Innovus Pharmaceuticals offers its products for men's and women's health, vitality, sexual and reproductive health, pain, vision and respiratory disease. The company provides its products to urologists, primary care physicians, gynecologists, therapists and directly to consumers through on-line channels, retailers and wholesalers. Innovus Pharmaceuticals is headquartered in San Diego, California, the US.

Innovus Pharmaceuticals Inc (INNV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249

Table of Contents

List of Tables

List of Figures

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Innovus Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase

Innovus Pharma Acquires Assets of Beyond Human for USD0.6 Million

Innovus Pharma Acquires Vesele from Trophikos

Innovus Pharma Amends Acquisition of Rights to Circumserum from Centric Research for up to USD7.5 Million

Innovus Pharma To Acquire Prescription Product Portfolio From Prospector Capital Partners II

Venture Financing

Innovus Pharma Raises USD0.33 Million In Venture Financing

Innovus Pharma To Raise USD1.1 Million In Venture Financing

Partnerships

Innovus Pharma Enters into Distribution Agreement with Laboratorios Q Pharma

Innovus Pharma Enters into Co-Marketing Agreement with DanaLife for Zestra

Innovus Pharma Enters Into Co-Promotion Agreement With Consortia Health For EjectDelay

Licensing Agreements

Innovus Pharma Enters into License and Distribution Agreement with Lavasta Pharma

Corporacion Pharma Solutions Peru Enters into Licensing Agreement with Innovus Pharma

Innovus Pharma Plans to Enter into Licensing Agreement with University of Iowa Research Foundation

Luminarie Enters into Licensing Agreement with Innovus Pharma

Innovus Pharma Expands Licensing Agreement with Densmore for Zestra

Innovus Pharma Enters into Licensing Agreement with NTC

Innovus Pharma Enters into Licensing Agreement with J&H Co. for Zestra

Elis Pharma Enters into Licensing Agreement with Innovus Pharma for Zestra

Innovus Pharma Enters into Licensing Agreement with Seipel

Innovus Pharma Enters into Licensing Agreement with BroadMed for EjectDelay

Khandelwal Labs Enters into Licensing Agreement with Innovus Pharma

BroadMed Enters into Licensing Agreement with Innovus Pharma for Sensum+

Innovus Pharma Enters Into License And Distribution Agreement With Ovation Pharma For Circumserum

Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma

Bio Task Enters into Licensing Agreement with Innovus Pharma

Elis Pharma Enters into Licensing Agreement with Innovus Pharma

Innovus Pharma Enters into Licensing Agreement with Tabuk Pharma

Innovus Pharma Enters into Licensing Agreement with Sothema Labs

Orimed Pharma Expands Licensing Agreement with Innovus Pharma

Innovus Pharma Enters into Licensing Agreement with Tramorgan for Sensum+

Innovus Pharma Enters Into Licensing Agreement With Ovation Pharma For EjectDelay

Equity Offering

Innovus Pharma Raises Funds through Private Placement

Innovus Pharma Prices Public Offering of Shares for USD3.9 Million

Innovus Pharma Files Registration Statement for Public Offering of Shares and Warrants for up to USD5 Million

Innovus Pharma to Raise Funds in Public Offering of Shares

Innovus Pharma to Raise USD0.2 Million in Private Placement of Shares upon Exercise of Warrants

Innovus Pharma Completes Private Placement Of Shares For USD0.13 Million

Innovus Pharma Completes Private Placement Of Shares For USD0.45 Million

Innovus Pharma Completes Private Placement Of Shares For USD4.5 Million

Debt Offering

Innovus Pharma Raises USD0.8 Million in Third and Final Tranche of Private Placement of 10% Notes Due 2017

Innovus Pharma Raises Additional USD0.75 Million in Private Placement of 10% Note Due 2017

Innovus Pharma Raises USD1.5 Million in Private Placement of 10% Note Due 2017

Innovus Pharma Raises USD0.5 Million in Private Placement of 5% Notes Due 2016

Innovus Pharma to Raise USD0.3 Million Private Placement of 5% Notes Due 2016

Innovus Pharma Raises USD0.1 Million in Private Placement of Notes

Innovus Pharma Raises USD0.1 Million in Private Placement of 8% Debentures

Innovus Pharma Amends Private Placement of 8% Debenture Due 2016

Innovus Pharma Raises USD0.3 Million in Private Placement of 10% Debentures due 2015

Innovus Pharma Raises USD0.4 Million in Private Placement of 8% Debentures due 2014

Innovus Pharma Raises USD0.1 Million in Private Pacement of Convertible Debt

Innovus Pharma Raises USD0.2 Million in Private Placement of 8% Debentures

Asset Transactions

Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma

Acquisition

Innovus Pharma Acquires Novalere

Innovus Pharma Acquires Semprae Labs

Innovus Pharmaceuticals Inc-Key Competitors

Innovus Pharmaceuticals Inc-Key Employees

Innovus Pharmaceuticals Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Financial Announcements

Nov 14, 2017: Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016

Aug 14, 2017: Innovus Pharmaceuticals Reports a Quarterly Net Revenue Increase of 99.2% and Net Loss Decrease of 74.1% Compared to the Same Period in 2016

May 12, 2017: Innovus Pharmaceuticals Reports Quarterly Revenue for the First Quarter 2017 of $2.2 Million

Mar 06, 2017: Innovus Pharmaceuticals Reports Record Annual Revenues for the Full Year 2016 of $4.8 Million

Legal and Regulatory

Dec 04, 2017: Innovus Pharma Files Application for the Commercialization of ProstaGorx for Benign Prostatic Hyperplasia ("BPH") as a Natural Health Product in Canada

Oct 18, 2017: Innovus Pharma Receives Approval from Health Canada for Vesele as a Natural Health Product

Product News

Nov 14, 2017: Innovus Pharma Launches FlutiCare OTC Nasal Spray Allergy Relief in the U.S.

Sep 19, 2017: Innovus Pharma Announces the Launch of Zestra in France, Belgium and Monaco by Its Partner, Densmore

Jun 01, 2017: Innovus Pharma Announces Positive Pre-Clinical Synergistic Effects of Vesele in Combination with Sildenafil on Nitric Oxide Production

May 24, 2017: Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States

May 01, 2017: Innovus Pharma Launches ProstaGorx Product for Prostate Health Through its Beyond Human Sales and Marketing Platform in the United States

Other Significant Developments

Jan 18, 2018: Innovus Pharma Announces Official Launch of its Amazon, Walmart, eBay and Wish On-Line Stores with a Combined 116 Product SKUs

Aug 09, 2017: Innovus Pharma Orders its First Commercial Batch of 220,000 Units of FlutiCare

Apr 05, 2017: Innovus Pharma Announces Receipt of Notification to Commercialize Zestra Glide in the European Union 9

Mar 02, 2017: Innovus Pharma Announces Receipt of Notification to Commercialize Zestra in the European Union

Appendix

Methodology

About GlobalData

Disclaimer

List of Figures

Innovus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018